high-dose quadrivalent influenza vaccine (GC3114A)
/ GC Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 05, 2019
Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
(PubMed, Vaccine)
- P1 | "In conclusion, GC3114 was safe, well-tolerated, and immunogenic in healthy adults. Clinical Trials Identifier: NCT03357263."
Clinical • Journal • P1 data • Geriatric Disorders • Infectious Disease
1 to 1
Of
1
Go to page
1